Gathering in Suzhou | 2024 xRNA Nucleic Acid Drug Development and Innovation Forum
Release Date:
2023-12-29 13:48
xRNA2024 Conference Information
The development of nucleic acid therapeutics has been marked by numerous ups and downs, but it has ultimately borne fruit, with widespread applications in the treatment of genetic diseases, cancers, viral infections, and other conditions. Small nucleic acid drugs offer distinct advantages, including rapid target identification, high success rates in drug discovery and development, a low propensity for resistance, broader therapeutic coverage, and prolonged efficacy. mRNA vaccines have also advanced rapidly in the context of the COVID-19 pandemic. With the maturation of in vitro mRNA synthesis and delivery technologies, the stability and translational efficiency of mRNA therapeutics have improved substantially, with the bulk of current applications concentrated in the vaccine sector. Moreover, mRNA holds tremendous potential for use in immunotherapy, protein replacement therapy, cell therapy, regenerative medicine, and other fields. According to projections, the global mRNA market is expected to reach US$23 billion by 2035.
The xRNA Nucleic Acid Drug Development and Innovation Forum will be held in Suzhou on January 16–17, 2024. On that occasion, nucleic acid vaccine and drug R&D experts from both China and abroad will gather to focus on next-generation mRNA/circRNA vaccines and therapeutics, oligonucleotide drug development, preclinical and clinical research, as well as delivery technology and process development, with the aim of accelerating industrialization and market penetration.
Hycells Bio and Beike Pharmaceuticals are fortunate to have also become pioneers in exploring services within the mRNA nucleic acid therapeutics field. As strategic development partners, Hycells Bio and Beike Pharmaceuticals consistently uphold a rigorous, pragmatic, and professional ethos, remain committed to innovation-driven growth, and work together to serve domestic and international clients and various institutions. Providing compliant, standardized, and end-to-end CRO services for the research, development, and evaluation of vaccines and infectious disease therapeutics.
At this exhibition, Hycells Biotechnology and Beike Pharmaceuticals will jointly showcase their vaccine and infectious disease drug R&D technology platforms, aiming to demonstrate these cutting-edge capabilities to a broader network of partners and industry peers. We look forward to collaborating with you at this prestigious event, sharing in the industry’s prosperity and achievements, and empowering more innovative pharmaceutical companies in their drug discovery and development efforts.
Booth Number: B1
xRNA2024 Conference Information
Meeting Time: January 16–17, 2024
Meeting Location: Suzhou, China
Conference Size: Approximately 1,000 people
Organizing Unit: Diyi Life Sciences Deliver Life Sciences
Collaborating and Supporting Organizations: National Biopharmaceutical Technology Innovation Center, BioBAY, Suzhou Biomedical Industry Science and Technology Town Mayor Group, Guangzhou Rare Disease Gene Therapy Alliance, Shanghai Biopharmaceutical Industry Association, Chinese American Biopharmaceutical Society (CABS), Zhangjiang Science and Technology Review
Main topics of the conference:
Topic One: mRNA and Circular RNA Vaccine/Drug Development
Topic 2: mRNA nucleic acid vaccine/drug process development and manufacturing;
Analysis and Quality Control
Topic 3: mRNA Cancer Vaccine Development
Topic 4: Innovative Applications of mRNA (Protein Replacement Therapy, Cell Therapy, Gene Editing, and Regenerative Medicine, among others)
Topic 5: Oligonucleotide drug development (siRNA, ASOs, etc.)
Topic Six: Oligonucleotide drug process development and manufacturing;
Analysis and Quality Control
Topic 7: Nucleic Acid Delivery Strategies and Technologies
Scan the code to register
Confirmed Guests and Topics for xRNA2024
mRNA/circRNA Vaccine and Drug R&D: Process and Delivery Focus
Research and development and application of tissue-targeted mRNA-LNP nanomedicines
♣ Cheng Qiang, Researcher and Doctoral Supervisor at Peking University
Progress in Innovative Applications of mRNA on the International Stage
♣ Xin Chunlin, Vice President of CanSino Biologics
Novel Lipid Nanoparticle mRNA Delivery System
♣ Li Jianguang, Chief Scientist of Haichang Biotechnology
Application of mRNA-Based Protein Replacement Therapy in Rare Diseases: Current Status and Challenges
♣ Yang Haitao, Founder and Chairman of Ruiyi Aona Biopharmaceutical
Related News
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how He Yousheng proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Recently, the research team led by Researcher Bian Yingjie at the Guangzhou National Laboratory, in collaboration with partners from Sun Yat-sen University, published a study titled “Iron overload in the tumor microenvironment induces CD8⁺ T cell ferroptosis and dysfunction” in the internationally renowned academic journal Nature Communications.
Hycells Recruitment | Never Stop Exploring, Never Stop Innovating
The company consistently upholds its core values of “people‑centricity, quality first, and innovation as the foundation,” remains driven by technological innovation, and sets new industry benchmarks for domestic innovation, thereby laying a solid foundation for the development and global advancement of China’s innovative pharmaceutical sector.
The HiXpan® NK Serum-Free Culture Kit, Version 3.0, is manufactured in strict compliance with GMP standards, and its production system fully adheres to relevant guidelines and regulations, including the “818 Requirements,” positioning it for pharmaceutical‑grade manufacturing and applications.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board